The Peter Attia Drive

→ WHAT IT COVERS Oncologist and Pulitzer Prize-winning author Siddhartha Mukherjee joins Peter Attia to examine fifteen years of cancer science evolution, covering how inflammation and random mutations drive cancer development, why early detection remains elusive, how CAR-T and immunotherapy are producing durable cures in blood cancers, and why regenerative failure of stem cells may be the central mechanism underlying aging itself.

→ WHAT IT COVERS Peter Attia revisits his strongest positions from 400 podcast episodes, examining how evidence and clinical experience have shifted his views on ketogenic diets, extended fasting, autophagy, and multiple longevity interventions over eight-plus years. → KEY INSIGHTS - **Keto mechanism shift:** Ketogenic diets work not through insulin suppression but through improved satiety and reduced energy intake — the same mechanism as other restrictive diets.

→ WHAT IT COVERS Peter Attia interviews Dr. Kathryn Gray, Division Chief of Maternal Fetal Medicine at the University of Washington, covering the full physiologic arc of pregnancy — from plasma volume expansion and hormonal shifts in the first trimester through gestational diabetes, preeclampsia, delivery decisions, and how pregnancy complications predict a woman's long-term cardiovascular and metabolic disease risk decades later.

→ WHAT IT COVERS Lloyd Klickstein, physician-scientist and drug developer with 20+ years at Novartis and multiple biotech companies, traces the complete arc of modern drug development using bimagrumab as a case study — covering target identification, antibody discovery, clinical trial design, FDA regulatory pathways, patent strategy, and why muscle-preserving therapies may reshape metabolic disease treatment.

→ WHAT IT COVERS Peter Attia examines thyroid hormone management, explaining why roughly 5% of U.S. adults have clinically meaningful dysfunction, why symptoms alone cannot diagnose it, and how both under- and over-treatment cause measurable harm. → KEY INSIGHTS - **Symptom Unreliability:** Fatigue, weight gain, and feeling "off" cannot distinguish hypothyroidism from euthyroid status in blinded clinical studies.

→ WHAT IT COVERS Cardiologist and lipidologist Michael Davidson joins Peter Attia to examine why LDL should be treated as a causal driver of disease from early adulthood, the history and science behind CETP inhibition, obicetrapib's clinical trial data across cardiovascular and metabolic outcomes, and emerging evidence that raising HDL via CETP inhibition may reduce Alzheimer's disease risk in APOE4 carriers.

→ WHAT IT COVERS Peter Attia covers blood pressure comprehensively — from the physiology of systolic and diastolic readings to the SPRINT trial's findings on aggressive treatment targets. He addresses accurate home measurement protocols, the cardiovascular, renal, and cognitive consequences of hypertension, lifestyle interventions with quantified effects, and the four first-line medication classes with their specific trade-offs.

→ WHAT IT COVERS Peter Attia interviews headache specialist Dr. Brian Grosberg, director of the Hartford HealthCare Headache Program, covering the classification, pathophysiology, and treatment of migraine, cluster, and tension headaches. Migraine affects 12% of the population globally — roughly one billion people — with women impacted three times more often than men, yet the condition remains chronically underdiagnosed and undertreated.

→ WHAT IT COVERS Peter Attia breaks down metabolic liver disease across four progressive stages — from metabolic stress to irreversible fibrosis — explaining how the liver functions as the central hub of systemic metabolism, affecting glucose regulation, cholesterol production, and cardiovascular risk in over 38% of adults worldwide. → KEY INSIGHTS - **Four-Stage Progression Framework:** Metabolic liver disease moves through metabolic stress, steatosis (fat accumulation), steatohepatitis...

→ WHAT IT COVERS Psychiatrist Linus Abrams, with 35 years of clinical experience, challenges the neurotransmitter-only model of mental health by examining how estradiol, testosterone, progesterone, thyroid hormone, and cortisol directly regulate mood, cognition, and psychiatric conditions. The conversation covers bipolar misdiagnosis, treatment-resistant depression, hormonal transitions across the lifespan, and the clinical realities of ketamine and psilocybin therapies.

→ WHAT IT COVERS Peter Attia applies a five-question evidence framework to evaluate gray market peptides, using BPC-157 and CJC-1295 as case studies. He categorizes peptides into three evidence tiers and explains why physician prescriptions, compounding pharmacies, and third-party testing fail to solve the core problem of missing human clinical data. → KEY INSIGHTS - **Five-Question Framework:** Evaluate any peptide by asking: Does it have a viable mechanism?

→ WHAT IT COVERS Jim Otvos, creator of the NMR-based LDL particle test, explains how a single blood sample analyzed via nuclear magnetic resonance spectroscopy can simultaneously measure cardiovascular risk through LDL particle number, insulin resistance through the LPIR score, chronic systemic inflammation through GlycA, and short-term mortality risk through the Metabolic Vulnerability Index (MVX), a composite score validated across multiple large population studies.

→ WHAT IT COVERS Peter Attia traces six landmark medical breakthroughs — statins, ACE inhibitors, PCR, GFP, CRISPR, and GLP-1 drugs — back to curiosity-driven basic science involving jellyfish, fungi, snakes, hot springs, salt ponds, and desert lizards, arguing that nature's four-billion-year evolutionary toolkit consistently outpaces intentional drug design as a starting point for medicine.

→ WHAT IT COVERS Peter Attia examines four environmental pollutants — air pollution, noise, light, and EMFs — establishing an evidence-based hierarchy for which exposures warrant action and which are overstated, with practical mitigation strategies for each. → KEY INSIGHTS - **Priority Hierarchy:** Environmental exposures rank well below sleep, exercise, nutrition, blood pressure, lipids, and metabolic health in health impact.

→ WHAT IT COVERS Neurologist and psychiatrist Gayatri Devi outlines how Alzheimer's disease and related dementias exist on a spectrum rather than as binary diagnoses, how biomarker-guided early detection is reshaping risk stratification, why anti-amyloid monoclonal antibodies like lecanumab and donanemab require personalized slow-titration protocols to reduce ARIA risk, and how multimodal treatment combining hormonal, immunological, and neuromodulatory interventions can stabilize or reverse...

→ WHAT IT COVERS Peter Attia consolidates research on muscle mass and strength training for longevity, covering why skeletal muscle predicts mortality more strongly than type 2 diabetes or hypertension, how progressive overload works across age groups, optimal protein intake targets, creatine supplementation, power training for aging adults, and programming frameworks for beginners through seasoned lifters seeking health span outcomes. → KEY INSIGHTS - **Muscle Strength vs.

→ WHAT IT COVERS Peter Attia and a colleague examine GLP-1 receptor agonists—including semaglutide drugs like Ozempic and Wegovy—and their effects on muscle and lean mass loss, bone density, fat distribution, and how exercise and nutrition modify outcomes. → KEY INSIGHTS - **Lean mass loss ratio:** Early GLP-1 clinical data showed roughly a 50/50 split between fat and lean mass lost—meaning a 10-pound loss yielded only 5 pounds of fat loss.

→ WHAT IT COVERS Reproductive medicine specialist Renato Tomioka explains endometriosis and adenomyosis — conditions affecting 10% and 20–30% of women respectively — covering the 5–12 year diagnostic delay, how MRI and specialized ultrasound have replaced surgical diagnosis, hormonal versus surgical treatment decisions, IVF pathways, and how female age drives a nonlinear rise in chromosomal abnormalities that makes egg timing critical.

→ WHAT IT COVERS Peter Attia examines why 42,000 American women die annually from breast cancer despite effective screening tools, covering how to assess individual risk using validated calculators, when to begin mammography, how annual and biennial screening compare on mortality outcomes, and which imaging modalities—mammography, MRI, or ultrasound—match different risk profiles.

→ WHAT IT COVERS Peter Attia and lipidologist Tom Dayspring examine how the brain manages cholesterol through a system entirely separate from peripheral circulation, covering APOE genotype variants (E2/E3/E4), their mechanistic links to Alzheimer's disease risk, how amyloid and tau pathology connect to neuronal cholesterol imbalance, and what statins, ezetimibe, omega-3 fatty acids, and the CETP inhibitor obecetrapib do—or don't do—inside the brain.